Regeneron Plunges From Open After Earnings; Stock Still Higher

Shares of high-flying Regeneron Pharmaceuticals REGN opened Wednesday's trading session strongly higher after reporting its Q2 earnings before the opening bell. Despite falling precipitously from the open, REGN shares are still up 4% on the day. The company reported net income of $76.74 million or $0.70 per share, compared to a net loss of $62.50 million or $0.69 per share, in the year ago period. On an adjusted basis, which is comparable to analysts' consensus, the company earned $101.68 million or $0.90 per share, compared to a net loss of $50.11 million or $0.55 per share, in last year's corresponding quarter. This came in well ahead of Wall Street analysts' consensus EPS estimates of $0.27. Revenues in the quarter were $304.39 million compared to $107.90 million last year. This was considerably more than the consensus revenue estimate of $257.05 million. Despite the fact that the stock is up around 4% on Wednesday, the stock may not be fully reflecting the strength of Regeneron's results. There were clearly a number of big sellers at the open on Wednesday which drove the stock down. In mid-day trading, REGN is attempting to recover and could test its recent highs in coming days.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsIntraday UpdateMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!